Richard Snyder, Ph.D.

Vice President, Science & Technology, Pharma Services
Alachua, Florida, USA

Key roles and responsibilities

Lead the science & technology team’s company wide initiative developing multi-generational manufacturing and analytical platforms used for the GMP production of advanced therapeutics, including viral, cellular, and nucleic acid-based modalities.

Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida; Adjunct Faculty Member, Institut National de la Sante et de la Recherche Medicale (INSERM), France; and assistant professor of pediatrics at Harvard Medical School
Experience in the advanced therapeutics industry spans over thirty-five years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
Author of more than 70 scientific publications and also eight U.S. patents
National and international committees, including Ad-hoc Member of the NIH Recombinant DNA Advisory Committee (RAC) 1999, 2000; Consultant, FDA Cellular, Tissue and Gene Therapies Advisory Committee, 2006-2009; ASGCT Viral Gene Transfer Vectors Scientific Committee 2007 – 2010; ASGCT Bio Industry Committee, 2017 – 2021; Scientific Advisory Board, Irish National Institute for Bioprocessing Research and Training (NIBRT) 2020-present; Steering Committee member and Manufacturing Subteam member, The Foundation for the National Institutes of Health Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (BGTC) 2021-present

Post-doctoral fellow at Johns Hopkins University School of Medicine
Doctor of Philosophy in microbiology from The State University of New York at Stony Brook
Bachelor’s degree in biology from Washington University in St. Louis